Inhibition of Basal and Pentagastrin-stimulated Gastric Acid Secretion after Treatment with Benzilonium Bromide and after Selective Proximal Vagotomy

Jaska, F

doi:10.3109/00365527709181706

Cited by 3 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anticholinergic inhibitor benzilonium has been compared in a controlled trial with selective proximal vagotomy. 9 After one year peak acid output was reduced by 49%' in patients taking the drug and by 66% in the vagotomised; the 24 vagotomised patients had none (19) or minimal (six) symptoms, but only 10 of the 23 medically treated were symptom free, 10 having occasional eructations and three more severe symptoms, two of whom had relapsed when they defaulted from tablet taking.…”

mentioning

confidence: 97%

Cimetidine and duodenal ulcer.

Baron¹,

Alexander-Williams²,

Bennett³

1979

BMJ

View full text Add to dashboard Cite

was asked by the BMJ to present a case for medical treatment for duodenal ulcer. His article, published below, was then sent to a surgeon and a physician and all three met to discuss the topic with one of the BMJ medical editors, Dr Tony Smith, acting as chairman. Working paperEffective rational treatment of duodenal ulcer disease, a life-long diathesis with bouts and remissions, is based on ill-understood pathophysiology: excessive acid enters the duodenum with peptic digestion and ulceration.Most (and parietal cell mass) below which duodenal ulcer disease is uncommon. Operative success in preventing relapse is proportional to the acid-lowering effect of the operation as well as the skill of the operator, so that nearly all, or merely most, or only some patients have their gastric secretion reduced by operation to safe levels.2Are drugs a satisfactory alternative ? Walan5 gave the anticholinergic 1-hyoscyamine in an optimum effective dose twice daily for two years to 28 patients and their course was significantly better than that of 28 patients on dummy tablets. Those who kept well had definite reductions of basal and maximal histamine-stimulated acid, whereas others could not tolerate an adequately acid-inhibitory dose because of side effects.

show abstract

mentioning

confidence: 97%

Cimetidine and duodenal ulcer.

Baron¹,

Alexander-Williams²,

Bennett³

1979

BMJ

View full text Add to dashboard Cite

show abstract

“…It reduces gastric acidity to a similar degree, has no known metabolic side effects and gives very little risk of bacterial overgrowth. Jaska [18] com pared a conventional antimuscarinic (benzilonium bromide) and vagotomy in a 1-year trial and found it similarly effective with regard to ulcer recurrence, but of limited acceptance because of side effects.…”

Section: Maintenance Treatment Of Duodenal Ulcermentioning

confidence: 99%

Clinical Significance of M<sub>1</sub> Receptor Antagonists

Stockbrügger¹

1988

Pharmacology

View full text Add to dashboard Cite

The M₁-selective antimuscarinic drugs pirenzepine and telenzepine moderately reduce gastric acid secretion without inhibiting smooth-muscle activity as much as nonselective antimuscarinics, e.g. atropine and 1-hyoscyamine. They hasten peptic ulcer healing and improve the symptoms of reflux oesophagitis. In combination with H₂ receptor antagonists they abolish gastric acid secretion almost completely and can therefore be used in high-risk peptic conditions. Long-term trials have to show whether they can form a medical alternative to parietal cell vagotomy. The effect of M₁-selective antimuscarinics on ‘nonulcer dyspepsia’ is equivocal, but they may possibly be useful in the treatment of spastic constipation.

show abstract

Effect of Selective and Non-Selective Antimuscarinics on Rectosigmoid Motility and Gastrointestinal Transit

Jaup

Abrahamsson

Stockbruegger

et al. 1985

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

In 12 healthy volunteers, a rectosigmoid motility index (RSMI) was measured when either placebo, 0.5 mg atropine, or 5 mg pirenzepine was given intravenously as a single dose, double-blind, in random order after a control period of 30 min. Compared with the control period, atropine gave a significant decrease of the RSMI during the entire recorded period of 90 min, whereas pirenzepine inhibited RSMI only during the first two 15-min periods. In another series of experiments, gastrointestinal transit was assessed by means of a radiographic marker method. In healthy volunteers, gastrointestinal transit was estimated (n = 20) and gastric secretion was measured (basally and after modified sham feeding; n = 10) during oral medication with placebo, 50 mg pirenzepine twice daily, or 17.5 mg benzilonium bromide twice daily. In 10 of the volunteers gastrointestinal transit was also estimated with 35 mg benzilonium bromide twice daily, and in the other 10 volunteers with 0.6 mg L-hyoscyamine twice daily. The number of retained markers was significantly lower during pirenzepine than during L-hyoscyamine treatment. Neither dose of benzilonium bromide changed the transit of markers. Compared with non-selective antimuscarinics, the effect of pirenzepine was differential: with equipotently acid-reducing doses the decrease of the RSMI after pirenzepine lasted shorter and gastrointestinal transit was accelerated.

show abstract

Inhibition of Basal and Pentagastrin-stimulated Gastric Acid Secretion after Treatment with Benzilonium Bromide and after Selective Proximal Vagotomy

Cited by 3 publications

References 8 publications

Cimetidine and duodenal ulcer.

Cimetidine and duodenal ulcer.

Clinical Significance of M<sub>1</sub> Receptor Antagonists

Effect of Selective and Non-Selective Antimuscarinics on Rectosigmoid Motility and Gastrointestinal Transit

Contact Info

Product

Resources

About